Additionally, GEPIA-based analysis showed that UBE2T was differentially expressed in different stages in adrenocortical carcinoma (ACC), invasive breast carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), ovarian serous cystadenocarcinoma (OV), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), LUAD, kidney renal clear cell carcinoma (KIRC), and thyroid carcinoma (THCA) (Fig. 1C, only significant results shown). Here, UBE2T is linked to thyroid gland carcinoma.